Diana V Do

Featured in: Favicon

aao.org

healio.com Favicon

hcplive.com Favicon

futuremedicine.com Favicon

managedhealthcareexecutive.com Favicon

ophthalmologytimes.com Favicon

academicpedsjnl.net Favicon

eyetube.net

Articles

Management of macular telangiectasia type 2 may be near

Jan 9, 2025 | healio.com | Diana V Do |Christine Klimanskis

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Macular telangiectasia type 2 is a progressive and relatively rare neurodegenerative disease of the macula that typically affects patients who are older than 40 years of age, more predominantly women.
VIDEO: Aflibercept 8 mg provides extended dosing intervals, visual benefits in DME

Nov 14, 2024 | healio.com | Diana V Do |Alex Young |Anthony DeFino |Diana Do MD

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME

Jul 29, 2024 | healio.com | Diana V Do |Anthony DeFino |Diana Do MD |Christine Klimanskis

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the ASRS meeting, Diana V.
VIDEO: Aflibercept 8 mg shows sustained vision benefits at 96 weeks

Nov 27, 2023 | healio.com | Diana V Do |Anthony DeFino |Diana Do MD |Eamon Dreisbach

You've successfully added Ophthalmology: Retina/Vitreous to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the AAO meeting, Diana V.
Response to Protocol V: Is Observation a Wise Approach to DME with 20/25 Vision?

Nov 9, 2023 | eyetube.net | Diana V Do |Ramin Tadayoni

Response to Protocol V: Is Observation a Wise Approach to DME with 20/25 Vision? Diana Do, MD, and Ramin Tadayoni, MD, PhD Show Description + The DRCR Retina Network's Protocol V study found that, in eyes with at least 20/25 VA and DME, observation was appropriate until visual decline occurred. To Diana Do, MD, and colleagues, it wasn't that simple.
Overview of nAMD and DME

Sep 22, 2023 | hcplive.com | Diana V Do

TranscriptDiana Do, MD: We're going to discuss a lot of clinically relevant material for both age-related macular degeneration (AMD) and diabetic macular edema (DME). Let me first talk about some of the important facets that we're facing in our clinical practice today. We know that both neovascular AMD and DME are extremely prevalent in our communities and there are vision-threatening complications with these diseases if they are not treated in a timely fashion.
VIDEO: Aflibercept 8 mg continues to show good results in DME through 2 years

Aug 14, 2023 | healio.com | Diana V Do |Anthony DeFino |Diana Do MD |Christine Klimanskis

Source/Disclosures Source: Do DV. Aflibercept 8 mg for diabetic macular edema: 2-year results from the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle. Disclosures: Do reports having financial disclosures for Boehringer Ingelheim, Genentech, Kodiak Sciences, Kriya and Regeneron. You've successfully added to your alerts. You will receive an email when new content is published.